Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL0011034 Injection in Healthy Chinese Adult Subjects
NCT07828470Phase 1Not yet recruiting
- Sponsor
- Hunan Kelun Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KL0011034 (3 arms), sponsored by Hunan Kelun Pharmaceutical. Primary endpoint: Number of reported Adverse Events at 24 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
KL0011034
Beyond the preview
Go deeper on NCT07828470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828470.